Kyverna Therapeutics (KYTX) Return on Capital Employed (2024 - 2026)
Kyverna Therapeutics (KYTX) posted Return on Capital Employed of 66.65% for Q1 2026, up 19.94% on a QoQ basis from 83.25% in Q4 2025, and down 222.0% year-over-year from 54.63% in Q1 2025.
Kyverna Therapeutics (KYTX) Return on Capital Employed (2024 - 2026) Analysis & Trends
Kyverna Therapeutics' Return on Capital Employed history runs 3 years deep, the most recent figure standing at 66.65% for Q1 2026.
- Quarterly Return on Capital Employed fell 222.0% year-over-year to 66.65% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 66.65% (down 222.0% YoY) and the FY2025 annual result came in at 64.63%, up 2668.0% from the prior year.
- Return on Capital Employed was 66.65% for Q1 2026 at Kyverna Therapeutics, up from 83.25% in the prior quarter.
- Across five years, Return on Capital Employed topped out at 28.45% in Q2 2024 and bottomed at 99.21% in Q3 2025.
- A 3-year average of 61.36% and a median of 64.43% in 2025 frame the typical range for Return on Capital Employed.
- Annual changes were most pronounced in 2025 — Return on Capital Employed tumbled 6081 bps — and 2026, when it sank 222 bps.
- Kyverna Therapeutics' Return on Capital Employed stood at 49.49% in 2024, then plunged by 68 bps to 83.25% in 2025, then rose by 20 bps to 66.65% in 2026.
- Business Quant data shows KYTX's Return on Capital Employed at 66.65% in Q1 2026, 83.25% in Q4 2025, and 99.21% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -31.80% |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 10.46% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -68.47% |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 21.10% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 10.19% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -68.84% |
| 10 | Kyverna Therapeutics | 440.57 Mn | 440.57 Mn | - | -66.65% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -66.65% |
| Dec 31, 2025 | -83.25% |
| Sep 30, 2025 | -99.21% |
| Jun 30, 2025 | -84.22% |
| Mar 31, 2025 | -64.43% |
| Dec 31, 2024 | -49.49% |
| Sep 30, 2024 | -38.40% |
| Jun 30, 2024 | -28.45% |
| Mar 31, 2024 | -38.12% |